Litigation Details for AMGEN INC. v. EMCURE PHARMACEUTICALS LTD. (D.N.J. 2018)
AMGEN INC. v. EMCURE PHARMACEUTICALS LTD. (D.N.J. 2018)
| Docket | ⤷ Start Trial | Date Filed | 2018-06-28 |
| Court | District Court, D. New Jersey | Date Terminated | 2020-05-28 |
| Cause | 15:1126 Patent Infringement | Assigned To | Michael Andre Shipp |
| Jury Demand | None | Referred To | Douglas Arpert |
| Patents | 10,092,541; 6,962,940; 7,427,638; 7,893,101; 9,872,854 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in AMGEN INC. v. EMCURE PHARMACEUTICALS LTD.
The small molecule drugs covered by the patents cited in this case are ⤷ Start Trial and ⤷ Start Trial .
Details for AMGEN INC. v. EMCURE PHARMACEUTICALS LTD. (D.N.J. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2018-06-28 | External link to document | |||
| 2018-06-28 | 23 | Amended Complaint | (“the ’854 Patent”), and 10,092,541 (“the ’541 Patent”) (collectively, “the Patents-in-Suit”). … United States Patent Nos. 7,427,638 (“the ’638 Patent”), 7,893,101 (“the ’101 Patent”), 9,872,854 (…infringement of the ’541 Patent in addition to the ’638 Patent and the ’854 Patent, on November 8, 2018… This is a civil action for patent infringement arising under the patent laws of the United States,… This is a civil action for patent infringement arising under the patent laws of the United States, | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
